Logotype for Oncoclínicas do Brasil Serviços Médicos S A

Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Oncoclínicas do Brasil Serviços Médicos S A

Q2 2025 earnings summary

14 Jul, 2026

Executive summary

  • Q2 2025 was marked by commercial and operational transition, with revenues flat sequentially as contracts with high-delinquency or low-margin payors were phased out, while growth continued with other clients.

  • Adjusted EBITDA rebounded 38.3% quarter-over-quarter, with margin expansion despite lower net revenues.

  • Net loss ranged from R$136.8 million to R$142.3 million in Q2 2025, reversing net income from Q2 2024, mainly due to lower operating leverage and higher financial expenses.

  • Cash flow consumption increased, driven by client delinquency, higher interest expenses, and growth capex.

  • Strategic initiatives included discontinuing low-margin contracts, headcount optimization (~400 reduction since Q3 2024), vendor contract reviews, capex reprioritization, and a strategic review of non-core assets.

Financial highlights

  • Gross revenue in Q2 2025 was approximately R$1,657.6 million, stable sequentially but down 3.8% year-over-year; net revenue fell 6.6% year-over-year to R$1,464.4 million.

  • Adjusted EBITDA reached R$185.1 million (12.6% margin), up 38.3% sequentially but down 41.7% year-over-year.

  • Net loss for Q2 2025 was R$142.3 million, with negative operational cash flow of R$196.1 million, mainly from late payments by discontinued clients.

  • Cash gross margin improved 250 bps quarter-over-quarter to 30.3%, but declined year-over-year.

  • Net financial result was negative R$175.1 million, a slight improvement from Q2 2024.

Outlook and guidance

  • Sequential revenue deceleration expected in Q3 2025 due to the end of services for Unimed FERJ and Unifers starting August.

  • Medium-term growth anticipated from new contracts, client base recycling, and new cancer centers and medical facilities.

  • Capex plan and non-core hospital operations under strategic review for reprioritization.

  • Saudi Arabia JV projected to reach US$550 million gross revenue and US$150 million EBITDA by year five, but remains pre-operational.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more